Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04199468 · ClinicalTrials.gov registry record · Phase 1
THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT04199468: Completed Phase 1 study, sponsored by Yale University.
NCT04199468 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04199468, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The aim of the research protocol is to evaluate cannabinoid-glutamate interactions in humans. As part of this aim the investigators will assess the safety and tolerability of the combination of NMDA antagonist, ketamine, and the cannabinoid, delta-9-tetrahydrocannabinol (THC), in healthy adult subjects, and characterize the interactive effects of ketamine and THC on various electrophysiological (EEG), cognitive, and behavioral outcomes.
Primary Outcome
The primary EEG outcome 1 will be EEG event related potential voltage amplitude (microvolts).
Interventions
- DRUG Active Delta-9-THC
- DRUG Placebo Delta-9-THC
- DRUG Active Ketamine
- DRUG Placebo Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-09-24 |
| Est. Completion | 2022-06-21 |
| Phase | Phase 1 |
What the finished NCT04199468 record still lists
NCT04199468 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 4 interventions - of which Active Delta-9-THC is the first listed.
NCT04199468 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04199468 about?
NCT04199468 is a clinical study titled "THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis". The aim of the research protocol is to evaluate cannabinoid-glutamate interactions in humans. As part of this aim the investigators will assess the safety and tolerability of the combination of NMDA antagonist, ketamine, and the cannabinoid, delta-9-tetrahydrocannabinol (THC), in healthy adult subje...
What is the current status of trial NCT04199468?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2019-09-24. Estimated completion is 2022-06-21.
What interventions are being tested in trial NCT04199468?
The interventions under investigation include: Active Delta-9-THC (DRUG), Placebo Delta-9-THC (DRUG), Active Ketamine (DRUG), Placebo Ketamine (DRUG).
Who is sponsoring clinical trial NCT04199468?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04199468's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI